Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Proteasome Inhibitors Induce Inhibitory κB (IκB) Kinase Activation, IκBα Degradation, and Nuclear Factor κB Activation in HT-29 Cells

Zoltán H. Németh, Hector R. Wong, Kelli Odoms, Edwin A. Deitch, Csaba Szabó, E. Sylvester Vizi and György Haskó
Molecular Pharmacology February 2004, 65 (2) 342-349; DOI: https://doi.org/10.1124/mol.65.2.342
Zoltán H. Németh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hector R. Wong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelli Odoms
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edwin A. Deitch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Csaba Szabó
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Sylvester Vizi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
György Haskó
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The transcription factor nuclear factor κB (NF-κB) is activated and seems to promote oncogenesis in certain cancers. A major mechanism of NF-κB activation in cells involves cytoplasm-to-nucleus translocation of this transcription factor after hydrolysis of the cytoplasmic inhibitor inhibitory κB (IκB) by the 26S proteasome. Because selective proteasome inhibitors have been shown to block IκB degradation; consequently, NF-κB activation in a variety of cellular systems, proteasome inhibitors were proposed as potential therapeutic agents for the treatment of cancer. However, under certain conditions, IκB degradation and NF-κB activation are not mediated by the proteasome system. We investigated how proteasome inhibitors affected NF-κB activation in the intestinal epithelial cancer cell line HT-29, which has been documented to have an atypical NF-κB regulation. Treatment of cells with the selective proteasome inhibitors carbobenzoxy-l-leucyl-l-leucyl-l-norvalinal (MG-115), carbobenzoxy-l-leucyl-l-leucyl-l-leucinal (MG-132), or lactacystin induced NF-κB activation as indicated by both an increase in NF-κB DNA binding and transcriptional activity. This increase in NF-κB activation caused by proteasome inhibitors was accompanied by an increase in IκB kinase activation and a degradation of IκBα but not IκBβ. Furthermore, proteasome inhibitors induced the expression of NF-κB target genes. In summary, these results demonstrate a unique effect of proteasome inhibitors on the IκB–NF-κB systems in HT-29 cells, in which proteasome inhibitors activate rather than deactivate the NF-κB system. We conclude that the use of proteasome inhibitors to block NF-κB activation in cancer cells may not always be a viable approach.

  • Received July 8, 2003.
  • Accepted October 21, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 65 (2)
Molecular Pharmacology
Vol. 65, Issue 2
1 Feb 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Proteasome Inhibitors Induce Inhibitory κB (IκB) Kinase Activation, IκBα Degradation, and Nuclear Factor κB Activation in HT-29 Cells
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Proteasome Inhibitors Induce Inhibitory κB (IκB) Kinase Activation, IκBα Degradation, and Nuclear Factor κB Activation in HT-29 Cells

Zoltán H. Németh, Hector R. Wong, Kelli Odoms, Edwin A. Deitch, Csaba Szabó, E. Sylvester Vizi and György Haskó
Molecular Pharmacology February 1, 2004, 65 (2) 342-349; DOI: https://doi.org/10.1124/mol.65.2.342

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Proteasome Inhibitors Induce Inhibitory κB (IκB) Kinase Activation, IκBα Degradation, and Nuclear Factor κB Activation in HT-29 Cells

Zoltán H. Németh, Hector R. Wong, Kelli Odoms, Edwin A. Deitch, Csaba Szabó, E. Sylvester Vizi and György Haskó
Molecular Pharmacology February 1, 2004, 65 (2) 342-349; DOI: https://doi.org/10.1124/mol.65.2.342
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The Regulation and Mechanisms of ImKTX58 on KV1.3 Channel
  • Human mAb 3F1 Targeting the Functional Epitopes of Siglec-15
  • Effects of Small Molecule Ligands on ACKR3 Receptors
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics